RxDoctor Payments Data

Jessica Basa, MD

Family Medicine · Barstow, CANPI 1952360539

Payments from drug & device makers

$609in general payments, 2019–2025

Across 19 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$207
  • Novo Nordisk$120
  • Corcept Therapeutics$84
  • Boehringer Ingelheim$39
  • Philips North America LLC$36
  • Dexcom, Inc.$28
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$609 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$114,570
Medicare patients
185
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$41,826
TrulicityDulaglutide28$36,020
OzempicSemaglutide37$32,975
JanumetSitagliptin Phos/Metformin Hcl23$26,907
XareltoRivaroxaban30$23,074
JanuviaSitagliptin Phosphate29$22,479
TradjentaLinagliptin25$19,382
EliquisApixaban18$10,884
Spiriva RespimatTiotropium Bromide19$9,903
Levothyroxine Sodium215$3,169
Atorvastatin Calcium341$2,563
Levemir FlexpenInsulin Detemir14$2,410
Gabapentin174$2,263
Albuterol Sulfate HfaAlbuterol Sulfate64$2,103
Metoprolol Succinate124$1,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$39$71,11181 claims
Novo NordiskOzempic$120$32,97537 claims
PfizerEliquis$17$10,88418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Barstow

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →